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Studies r eporting a high concentration of WR-2721 in mouse sal i-
vary gl ands led to ou r studi es of possible r adioprotection of these 
glands by t his drug f rom ionizing r adiation . Or al effects of radiation 
in the presence of \<R- 2721 were s tudied in mice and doge . Histologi cal 
evaluation of mouse salivary glands irradiated with 1000 rads of 60Co 
showed essentially no difference bet ween contro l and experimental 
animals . Almost full regeneration of t he serous sal ivary components 
occurred by 6 months i n both groups and nei ther group had changes in 
the mucous glands . The use of higher doses o f radiation in th e mouse 
was prevented by the oral cavit y death syndrome (LD50/ B-IO) which was 
r educed by a factor of 2.1 when WR- 2721 was given 30 minutes before ir-
radiation of the head. Salivary function in mongr el dogs measured at 
weekl y int ervals fo r one month following rad ia t ion s howed no significan t 
difference in control and experimental anin~15; therefore the salivary 
gland may be an organ capable of metabolizing or exc r eting of \<R-272 l. 
Ma r ked protection from acute radia tion damage of the skin and or a l 
mucosa was observed in dogs receiving WR-2721 prior t o treatment with 
radiation. A dose modifying facto r of 1.67 was obtained for these 
st ruc tures . If s uch normal tissue sparing could be ach i eved clinically, 
higher doses of radiation could be used in treatment of head and neck 
malignancies, thereby increasing the probability for s uccess f ul radi-
ation therapy for such tumors. 
INTRODUCTION 
Cancer, characterized by potential i nvasion of healthy tissues, 
metastases to other parts of the body, and unlimited cell growth, is 
the second leading cause of death in the United States . In 1971, fo r 
example , 17.5 per cent of all deaths was due to cancer (4). 
Cancer is a lso a major cause of death throughout the world. Sur-
vival rates for individuals with various types of cancer have been in-
creased . The survival rate increase for individuals with some types of 
cancer has been striking , while in others, the survival ra tes have de-
creased or leveled off. The survival rates for i ndividuals with 
certain forms of cancer have shown no change during the past twenty-
five years. There hns been an overall decrease in cancer incidence and 
morcality, but some types of cancer (e. g ., lung, pancreas, colon, 
prostate, and bladder) have incr~ased. 
Recent signif i cant progress in the area of cancer treatment can be 
explained by three fac t ors: (1) diagnosis of the disease in an early 
localized state, (2) treatment of the cance r within four mon t hs of 
diagnosis, and (3) development of new diagnos tic and therapeutic tech-
niques and devices . It should be noted that, even with the new ad-
vances, many curable patients will contiIlue to die of cancer be~ ause 
they escaped early detection and cannot benefit from modern therapy 
when their diseases are in early stages. As new diagnostic and thera-
peutic methods are deve loped and us ed, trc.11 s in treatment plans change. 
In the treatment of breast cancer, for example, survival rates recorded 
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during the period from 1950-1959 have been significantly improved (4) . 
Since the 1950's, patients have received less surgical treatment and 
mo~e adjuvant therapy with radiation, chemotherapy, and /or hormones . 
This study is limit~ ~o the investigation of radiation effects 
related to radiotherapy o f head and neck cancers . Nedical care is 
concerned primarily with patient support during and after the stress 
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of treatment in patients with head and neck cancers . A careful medical 
history and physical examination should be performed as an aid in pro-
viding the bes t medical ca re possible. During the course of patient 
exami.nHion all bodily functions s hould be considered by the physician. 
Pulmonary function and cardiac status, for example , should be carefully 
evaluated and current and/or pas t medical or surgical diseases should 
be noted. All these factors play an important role in deciding which 
treatment plan will be followed. When i t has been determined that 
radio therapy is applicable as a therapeutic means, a trea tment plan 
is made out which may lequire tha t the patient be treated with 6000-
7000 rads (radiation absorbed dose ) of 60Co therapy delivered in frac-
tionated doses over a period of six to seven weeks . 
Figure I shows, for example, a 52-year-old male patient who de-
velopeo an epidermoid car~inoma of the anterior tongue. Figure 2 
shows the same patient six weeks later after he had received 6000 rads 
of 60Co therapy through bilaterally opposed ports. The therapeutic 
results were lis ted as satisfactory. Skin cancers detected early 
usually require less total radiation for successful trea tment. Figure 
3 is a photograph of a patien t who developed squumous carcinoma of the 
skin. The treatment of this patient consisted of 5500 rads of 60Co 
therapy delivered through a single lateral field over a per od of five 
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Figure 1. 52-year-old male pat ient wi th an epidermoid carcinoma of t he 
anterior tongue. Courtesy of Department of Radiation 
Medicine, University of Kentucky Medical Center. 
Figure 2 . Same 52-year-old male patient six weeks following eradication 
of the epidermoid carcinoma with 6000 rads of 60Co therapy. 
Courtesy of Depa rtmen t of Radiation Medicine, University of 
Kentucky Medical Center. 
-; 
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Figure 3. 
Figure 4. 
~~le patient with a pre-auricular squamous carcinoma. 
Courtesy of Department of Radiation Medicine, University of 
Kentucky Medical Center. 
Same male pat1ent five weeks following eradication of the 
ca rcinoma with 55LO rads of 60Co therapy. Only a small 
pre-auricular ulcer remains. Courtesy of Department of 
Radia tion Medicine, University of Kentucky Medical Center. 

weeks. Figure 4 is a photograph of this patient taken after therapy 
for the cancer was completed. 
An OPtimal selective effect i n radiotherapy is reached when the 
tumor is complet e 1 ., destroyed wi thout significant functio nal or 
structural injury co t he sur ro unding normal tiss ue. It should be 
POinted ou t tha t a c~rt a in amount of damage t o the normal tissue mus t 
usually be accepted a l ong wi th the erad ica tion of the malignancy, as a 
truly selective effec t is not very often reached. 
Since radiation spa r es no biological structure , the amount of radi-
a tion administered must be limited both in volume of tissue treated as 
well as in rota l dose during r adiotherapy. The therapeutic ratio must 
be Conside red in order to keep the normal tissue injury at a minimum 
and still give an effective tumor dose. The therapeutic ratio i s de-
fined as the relationship between the tumo r lethal dose and normal 
tissue tolerance (19). Radiotherapy i s limited by this ther apeutic 
ratio because no radiation effec t is selective for the mal i gnancy alone . 
Further studies dea ling with the modification of the therapeutic ratio 
will therefore be likely to yield useful information. McJification of 
the therapeutic ratio might for example permit curing of non-curable 
malignancies beca use highe r doses of r adiation could be used. A useful 
mOdi fication of the therapeutic ratio Could res ult from the use of agents 
which could protect the normal tissues while providing no protection to 
the cancerous tiss ue s . 
Chemicals that act as radiosensitizers and radiopro tectors are 
known. Radios enSitizing agents enhance the rad1ation effects, whereas 
radioprotecting agents prOvide an apparent protection against the 
effects of radiation . These agents tend to have similar eff ects upon 
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normal and rr~lignant tissues . An agent which could simultaneously 
protect thE normal tissues and sensitize the malignant cells would be 
most useful, bu t no such agen t is known . The present study is con-
cerned wi th a • ' .g, S- 2-(3-ami nop ropylamino)ethyl phosphorothioate 
(l1R-2721). "' hl c~ has been shown to protect normal tissues but not the 
malignanl'" on e.":> ( 17) . This di fferential protec tion may be due, in part, 
to dif f e rent concentrations of th e drug in the healthy and malignant 
ti ssue$. The purpose ot t hi s s tudy is to evaluate the radioprotection 
affo rd eu by this J rug to head and neck structures in do gs and mice. 
Uecause high concen tra tions of this drug have been demonstrated in the 
salivary glands of mice, the present investiga tion evaluating the radio-
protection afforded by this compound can indicate whether or not the 
compound has potential for use in radiation therapy of cancers . 
Significant cont ributions to the knowledge of radiation effect s 
have been made through the studies on compounds which modify ionizing 
radia tion. Bee t- use of the severe toxicity which was produced in animal 
sys t ems, early studies on radiopro t ectors were disappointing . The re-
birth of interest in radiop rotection i n the United States can pr obably 
be accounted for by the discovery of a thiophosphate compound (WR-2721) 
which was found t o ryrovide protection to normal tissues but not to 
cancerous tissues in a tumor-bearing mouse following radiation (30) . 
Thiophospha tes have been the major compounds inves t igated for a role in 
radioprotection . The mo s t prominent of these radioprotectors a re 
listed in Ta ble I (II). 
The phosphorothioate rad i oprotective agents were first synthesized 
in 1959 (1) . Later studies showed that these agents protec.t against 
ionizing radiation (2, 10, 28). Recent studies indicate that the new 
6 
MEA 
WR-2529 
WR-2721 
WR-2823 
WR- 638 
TABLE I 
MOST PROMINENT THIOPH05PHOROTHIOATE RADIOPROTECTIVE CO~~OUNDS 
Designation/Name of Compound 
8- mercaptoethylamine (cysteamine) 
3- (2-mercaptoethylamino)propionamide p-toluenesulfonat e 
S-2-(3-aminopropylamino) e thy l phosphorothioc acid hydrate 
S-2-(5-aminopentylamino)ethyl phosphorothioc acid mono-
hydrate 
Sodium hydrogen S- (2- aminoethy l )phosphorothioate 
Struc ture 
o 
• 
HSCH/, rl l HCH2CH 2CNII2 'CH3C 6H 4 50 3H 
radioprote ctive pho s phoro t hioate compounds a re l e ss tox ic than th e 
previously s tudied radioprot ectors . WR- 272l has been "hown to give 
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t he grea t es t protection o f any of these compo unds (1 2 , 17), Because 
WR- 2721 has been s howr : 0 pr ovide a high degree of prot ect i on in 
s eve ral no rmal tissues while providing only minima l pro t ec tion f or 
tumors) it has become a s i gni fican t drug fo r use in s tudies o f radio-
protection. The toxicity produced by this drug i s within a n acceptable 
range . 
The pr ocess by which WR-2 72l ente r s the ce ll has been de s cribed (27). 
Upon entry i nto the ~e ll, the compound becomes dephosphorylated ~nzy­
matically , thus exposing the s ulfhydry l gr oup. It i s thought that this 
proces s occurs f ast enough that no intact t<R- 2721 i s left inside the 
ce ll. Norma l cells and tumor cells show identical ce ll membrane perme-
ability to this drug , and bo th cell types readily dephosphorylate the 
compound. However, since the drug enters the ce l l by passive diffusion, 
less absorption would be expected to occur in a solid tumo r because the 
tumor is poorly vas cularized. This preve nts celivery of large concen-
trations of WR-27 21 to the tumor cells (1 2). 
The mechani s m by wh i ch WR-2721 pro t ec t s t he ce ll from radiation i s 
not certain. It i s thought that it may work by the same mechanism(s) 
propos ed for all sulfhydryl radioprotec tors (7): (1) removal of free 
radical s f ormed by radiation, (2) repair by donation of hydrogen atoms, 
(3) interac tion with cellular pro teins, (4) production of hypoxia in 
the tiss ues, and/or (5) delay of cellular division or inhibition of 
mitosis. 
I~ the mechanism is by free radical removal, then it is suggested 
that free radicals produced by radiation, such as the hydroxyl radica l, 
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oxidize the protective :j.gent, therefote fo rming a resonance-stable 
free radical which is not capable of reacting with the cellular com-
panents. If the free radicals act as oxidizing agents they are there-
fore preven ~ p from reacting with cellular components. It was found 
that the oxida t ion of radioprotectors, including WR-272l, indicates 
that they are capab l e of reacting with the radicals which are produced 
by the radiation (15). 
It i s possible that the protec tive agent can donate a hydrogen atom 
to a molecule which was conve rted to a free radical by radiation. Thus 
t he injured mo l ecule would be restored to its original or normal state 
upon acceptance of the hydrogen atom (6) . 
If the protective agent reacts with cellular proteins, the free 
sulfhydryl groups could form mixed disulfide bonds with the sulfhydryl 
groups of the proteins. Upon attack by a radiation-induced free 
radical, one sulfur atom of the disulfide is oxidized while the other 
is reduced. Consequently, the protein is not damaged by radiation. 
This mode of action is illustrated in Table I I . It should be noted 
that the protein could be oxidized which would leave the protein 
altered . This alternative route would allow for only 50 per cent of the 
radic.a l interactions to damage proteins, hence leaving 50 per cent of 
the proteins protected from t his type of oxidation (7) . 
The damaging effects of radiation are enhanced in the presence or 
oxygen, and a state of hypoxia provides protection from the radiat!on. 
Since thiol compounds are very easily oxidized, it has been theorized 
tha t tissue oxygen would be used up during such oxidations, hence 
leaving a state of hypoxia. One investigation tended to support this 
theory (29). This study showed that upon injection of WR-272l 
. " 
. -
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TABLE II 
POSSIBLE RADIOPROTECTIVE MECHANISM WITH MIXED DISULFIDE FORMATION 
~H2 
I 
R 
I S (~lixed Disulfide) 
I 
S 
I 
PROTEIN 
(Radical) .. 
NH2 I PROTEIN 
R (Radioprotector) + I I SH 
SH 
NIH2 
R 
J 
I 
S 
I 
PROTEIN 
(Mixed Disulfide) 
ALTERNATIVE ROUTE 
(Radical) .. 
SII 
+ I PROTEIN 
NH2 
I 
R 
I 
S (Mixed Disulfide) 
I 
S 
I 
PROTEIN 
NH2 I 
R 
I 
+ 
S02 
I 
PROTEIN 
SH 
Oxidation of proteins t akes place when this alternative route occurs. 
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vasodilation is produced and 1s prominent in the spleen . The vaso-
dilation of the spleen alters the blood supply to the rest of the body 
and does so in such a way as to reduce tissue oxygen tensions and 
thereby elevates r~ · ; r.~ ion resistance. It was pointed Qut that vaso-
dilation may be a un i versa.l effect of 1-'R-2721, but if this is so, it 
should not prevent the use of 1-'R-272l in radiotherapy in man. In the 
event vasodilation does not take place , a larger amount of WR-2721 
would be expected to be tolerated. 
If t he mechanism involves a delay in cell division, there may be 
more time available for repair of damage caused by radia tion. If the 
lTIechanism invo l 'Jes mitotic inhibition, it could be in such a way as to 
ar rest the cells in a radioresistant stage, therefore providing pro-
tection from the radiation. 
Because there are exceptions to all the above mechanisms, the 
radioprotection provided by WR- 272l probably results from a combination 
of severa l mechanisms . There are , for example , compounds which form 
disulfides but give no protection (7). CysteQmine has shown protection 
unrelated. to hypoxia (7). There are molecules with functional group 
distributions in structures similar t o those in the resonance-stable 
free r adicals formed by radioprotec tors which do no t give protection (7). 
Hore research i s needed before the mechanism or mechanisms through which 
protection is afforded can be explained adequately . 
Hetabolism st udies in rat s (22) have indicated that the main ex-
cretion of ~~-272l occurs through the feces. The second most important 
route for excretion i s in the urine. About 74 per cent of the total 
drug administered was excreted during the first 24 hours following oral 
administration of ~~-272l and about 94 per cent after 48 hours. Only 
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about 6 per cent waB retained. It was found that about 1.35 per cent 
of the total drug re tained was concentrated in the s elec ted organs 
(e . g., eyes , brain, hea rt . lung , liver, kidne y , sp l een), 0 . 09 per cent 
by the I" o,d. 0 .01 pe r cent by the muscle, 0.02 per cent by the fat, 
1 ~9 per cent by t he gas tro intes tinal tract, and 3 . 31 per cent by the 
carcass .'::'\l d r emaining vis c era. Observa tions of the excretory products 
during t he 48 hours following administration showed both the urine and 
fec e s to be of normal co lor and consistency. Autopsy of the animals 
a fter 48 hours showed all organs to be normal except the lungs of one 
animal (a total of three was used) which appeared spl.otchy in color. 
A second study (23) was done using twice the amount of "~-272l per gram 
of body weight with es sentia lly the same results as those listed above. 
The studies mentioned above reported that the drug crosses the 
blood-brain barrier, but that the amount crossing the barrier was less 
than 0.01 per cent of the total amount administered to the animal. 
This figure included the combined amounts whi ch enter the eyes and 
brain. In a recent study, it war reported that the brain, one hour 
following intravenous inJ~ction of WR-272l shows very little con-
centration of the drug (25). An earlier study reports that the drug 
WR-272l does not cross ove r the blood-brain or placental barriers (20). 
However, radioactivity wa s reported around the cerebral blood vessels 
and choroid plexus. Neve rtheless, this radioactivity seemed to be very 
low. 
High localization of WR-272l has been reported in the hematopoietic 
tissues, gastrointestinal and urinary tracts, and in some glandular 
tissue with maximum concentrations in the tissues between 1-4 hours 
following admin~stration (20). The blood appears to be cleared of the 
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drug within 5 minutes. The major si t e of me t abolism of the drug seema 
to be the live r with most of the elimination of the drug taking place 
via the gastrointestinal and urina ry tracts within 48 hours following 
administration . 
Th e main route of excret ion of \ofR-27 21 seems t o be via the gast ro-
intestinal and urinary trac ts. The live r s hows high concentrations of 
the drug, and it appears to be the area of greatest metabolism of the 
drug . Other sites of high concentrations include the hematopoietic 
tissues and glandular tissues . The submandibular salivary gland had 
been shown to have a great densit y of the drug (25). 
Autonomic and acute cardiovascular effec t s of lVR-2721 have been 
found to be slight with cumulative intravenous doses of up to 600mg/kg . 
These effects were studid in cats and dogs (5). Only small increases 
in femoral blood flow were produced by 1<R- 2721 whereas a similar 
phosphorothioate produced a marked increase . A slight depress ion in 
blood pressure of 5-15 mID Hg was noted which lasted for 5 minu t es but 
was followed by a gradual increase of 30-40 mm Hg . A depression of 
15-30 heart beats pe r minute was ob tained from WR- 2721 . The carotid 
a rtery occlusion pressor response was reduced by WR-2721 thirty minutes 
following injection, whereas it was not reduced by the other similar 
phosphor othioates . Lower doses (one-half as much) of the other 
phosphorothioates produced much greater depressive effects which lasted 
for longer periods of time. This indicates that WR- 2721 is not as toxic 
as similar phosphorothtoates. 
Indications that WR-2721 may ac t as a ganglionic blocking agent 
are evidenced by its ability to differentially block the effects of pre-
ganglionic nerves leaving the post-ganglionic nerves unstimulated. 
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Other effects noted from WR-2721 injection i nclud pd slight mydriasis 
and a watery type salivation. 
Duri ng the course of rad io th e rapy of head and neck cancers, compli-
cations may be in troduced '_J" , h are associated with the skin, mouth 
and throat , and salivary gl and s (15) . With the use of high energy 
60 
sources such as Co gamma rays, s kin reactions a re usually minima! , 
whereas with kilovoltage x-rays (orthovoltage ) intense s kin reactions 
may be noted. Two to four weeks follol<ing radia tion is the period of 
most intense skjn reactions. At l ow rad iation doses, erythema, pigment 
loss, ane dry desquamation may develop. At higher doses, moist de-
squamation and late necros is may develop . The area affected in skin 
reactions usually conforms with the field size used during the treatmen t. 
Dryness of the mou th and throat i s a common complaint of patients 
receiving head and neck radiation. Difficulty in swallowing may 
accompany the dryness. Thrush may develop within the mouth following 
irradiation wit h 60Co or x-ray . The dryness i s due to the radiation 
effects on the salivar y gl ands. 
Salivary gIQp.d~ are classifi ed as highly radios ensitive organs 
because o f the rapid effect raci iat ion has on their function. But, 
since epithelial gl a nds divide only rarely, the saliva ry glands could 
be expected to be radioresistant (18). 
As early as one day post-irradiation , t he salivary glands may 
show rapid and ma r ked swelling. This effect may be ac~ounted for by 
the changes in the endothelium of the vasculature, congestion and in-
creased permeability of capillaries, interstitial ede~a and acute 
infl ammatory cell i nfiltration, narrowing of the excretory duct due to 
edema and inflammatory pressure, swelling of duct linings or plugging of 
lumina by mucous. These chang~ s could stop or al ter the function of 
the sa livary glands. Necrosis and cell degene ra tion may be a conse-
quence. 
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Hu,", " ,.aliva r y glands s urgically removed 24 hours following singl E 
doses of radia tion show a parallel be tween the location and degree o f 
a cute inflammatory cell infiltration and cell degeneration. These two 
changes occur mostly in the serous cells and a re considered dose-
dependent. Inflammatory infiltration includes inva 31.on l..:. pt;.lymorpho-
nuclear leukocytes, eosinophilic leukocytes, and plasma cel ls along the 
septa and around acini (alveoli). Sometimes l umina appear to be full 
of exudate from degenerating leukocytes and acinar cells. Degene rative 
vascular changes appea r in the cells, produc ing vagueness in acinar 
outline and cleavage of the cells from their basement membranes. 
Pyknosis is present. Zymogen granules pool in acini and some gl a nds 
show a decrease in zymogen granules. 
The ~rimary damage seems to occur in the s e rous cells, although the 
mechanism of tissue reaction is not known . It may be tha t serous se-
cretion (with the enzyme amylase) could enter capillaries allered by 
radiation causing the inflammatory response noted earlier since there 
are capillaries between sero us acinar cells and not in mucous cells. 
Henc e the serous epithelia l degeneration could be a secondar y effect of 
radiation. The lack of mucous cell degener&tion could be due t o the 
fact that the mucous secretion does not enter the a ltered capillaries 
if indeed this is the case. 
The changes mentioned above fo :· single doses also appear if the 
radiation is delivered in fractionated doses, but the changes develop 
progressively. 
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Ac i nar ce l ls show transi~nt or abor t i ve signs of secretion or 
mitotic regene ration, bu t these are f ollowed hy progressive degene r-
ative processes . Recove ry of duc ts is usually mo re marked. The rell tl 
lost earlieL by t " .!xc r etorJ ducts. fo r example I aX l . J ~ced by 
mit otic u~tivity . The excretory duc t epl I.e i , ~ : V laL e r shu,,", 
" 
squamous D' ~ t al s i a or t Yr~r~ fa, Functiona l '.~ nefticient acin i 
may be product b ~ the inter ~ la ted duct s as ac ini a re progress ively 
lost. 
The sal ivary glands a re firm, smal l e r than normal , and s trongly 
adherent t o the surroundin g tiss ues a t the end of the acute clinical 
period, The main his toi ogica l changes at the end of this pe riod in-
elude : (1) i nterlobula r fibrosis, ( 2) inte r s titia l fibrosis and sc le-
r osis with i nfiltration of inflammat ory cells, (3) loss and a tr~phy 
or i nvolution of acini, (4) foci of necrosis in acini , and (5) meta-
plasia, 
There are thrpe major pairs of salivary glands in a l mammals (19), 
These compound tubulo- alveo12r glands a r e known as (1) pa rotid, (2) sub-
lingual , and ( 3) s ubmandibular, The salivary glands are composed of 
serous and mucous cells. The parotid gland a ar e composed entirely 
of the serous type. Although the submandibular and sublingual glands 
a r e both mixed glands (se r ous and mucous) , the submandibular glands 
are a lmos t all serous, whereas th e sublingual glands are almost en-
tire ly mucous. The t ypical gland consists of a secretory portion, the 
alveolus, connected to a system of tubes which termInate with an open-
ing in the oral cavity (3). Connective tiss Je septae run through the 
gland separating groups of alveoli into gland lobules. Narrow channe ls, 
the i nt ercalated ducts which are composed of cuboidal ce lls, lead 
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directly f rom the alveoli. 
While these ducts a r e long in the parotid glands , they are s hort in 
the submandibular and sublingual glands and even sometimes absent 1n 
the sublingual glaM .. Numerous infoldings of the basal part of the 
cell membrane, assoc ia teo with mitochondria, forms the striated ducts 
which leud from the intercalated ducts. Striated ducts lead to the 
l a r ger interlobula r ducts which lead to the intralobular ducts which in 
turn unite to form a single , terminattng excre tory duct composed of 
columnar epithelium . Toward the opening of the exc r e tory duct in the 
oral cavi ty, the epithelium becomes pseudostratified. 
The excretory duct of the parotid gland opens into the vestibule of 
the mouth just opposite the second molar tooth . The excretory duct of 
the submandibular gland opens near the side of the frenulum of the 
tongue . Parts of the sublingual gland open into the excretory duct of 
the submandibular while other parts open through a single excretory 
duct near the opening of the submandibular gland . 
The secretory cells of the glands are both mucous and serous. 
Zymogen granules, intracellular concentrations of ptyalin, give the 
cytoplasm of serous cells a granular appearance . The rounded nucleus 
is found toward the ba c.al end of the cell . The basal end of the cell is 
strongly basophilic due to a high content of RNA . Associated with this 
area are the ribosomes of the endoplasmic reticulum which produces the 
protein of the z>~ogen gr anules (24 ). 
The cytoplasm of the mucous cell stains very lightly when stained 
with hematoxylin a nd eosin. The mucinogen (precursor of mucin) con-
tained within che mucous cell gives the cell its characteristic I'emp ty" 
look upon staining. Usually this mucinogen is lost during preparation 
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for staining, hence the cytoplasm has a vacuolated appearance. The 
nucleus of the mucous cel l is flatteued and close to the base of t he 
cell . 
A goo "'.ood supply f urnishes the salivary glands their nourishl!1ent. 
. 
The Iaeger vesse ls are found in the septae between the lobes and a 
capillary plexus forms around the a lveoli. Both sy~athet ic and pa ra-
s ympathetic nerves innervate the salivary glands. 
The mucous cells secrete mucin which is a ~lear, viscous substance. 
Secretion of serous cells is thin and watery consisting of an ~lectro-
lyte solution. The parotid gland secretes ptyalin, an amylase re-
sponsible fo r splitting sta r ch and glycogen enzymatically into maltose . 
Upon stimulation of e ither th e s ympa the tic and parasympathetic nerves, a 
flow of "juices" is produced. Nerve stimulation also increases the 
flow of blood to the glands (21). Saliva contains electroly t es with 
+ + -the main ones being Na , K , HC03 , and CI. The composition of saliva 
is usuall~ related to the nature of the food eaten . 
Approximately one liter of saliva is produced daily by man . The 
submandibular glands produce two- thirds of thi s amount, the parotid 
glands produce one-fourth with the remainder produced by the sublingual 
and other sm~ll glands (buccal). Saliva may be modified by the striated 
ducts with their secretion of water and inorganic salts. Saliva is im-
portant for aid in swallowing and tasting food. It also helps maintain 
oral hygiene . Salivary glands play an enzymatic role; for example, 
ptyalin, mentioned earlier. An antimicrobia l role is also attributed 
to saliva, probab l y be cause of the t hiocyanate ion present. 
The salivary glands have been shown to have a high concentration of 
WR-272l following administration of the compound. The salivary glands 
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are nearly always involved during t he radiotherapy of head and neck 
tumors . WR- 272l has been shown to afford a high radioprotective effec t 
to some normal tissues while providing only minimal protection to the 
tumo r; this E . ''''.:5 to be relate d to dif ferent, concentrations of the drug 
in the two differ ent tiss ues. This s tudy is concerned with the evalu-
a tion of this drug for the possible radioprotection afforded to t he 
salivary glands , skin, and oral mucosa of the oral cavity . 
f~Tr.RIALS ~~ ~ffiTHODS 
Mice we re used to study the oral radiation dea th syndrome and the 
effects of radi ation on the histology of the salivary glands with and 
without WR-272l. All mice used were female, white, and of inbred strain 
Balb/c. They were purchased a t the age of 5-7 weeks from the Texas 
Inbred Company, Houston, Texas. The mice were not used for experiments 
until they ~ere at least 7-9 weeks old. All mice were housed in 29 cm 
long x 18 cm wirle x 12.5 cm high polystyrene cages. They were fed and 
watered ad libitum. The average weight of the mouse was 20 grams. 
The mice were divided into two major groups for the oral radia tion 
death study . One group received WR- 272l (supplied by Dr. Melvin Heiffer, 
Walter Reed Army Hospital , Washington, D.C.) and radiation while the 
other group received only radiation. The drug-treated (experimental) 
group was anesthesized with 0.05 mg Nembutal Sodium Solution, U. S.P . 
(sodi um pentobarbital, 50 mg/ ml) injec ted intraperitoneally (Jelco 
sterile, disposable syringes with Jelco sterile, disposable 25 gauge, 
5/8" bevel needles) 45 minutes prior to radiation. Fifteen minutes 
later (30 minutes prior to radiation) this group was injected with 
500 mg/kg WR-272l intraperitoneally. The drug was dissolved in 
Bacteriostatic Sodium Chloride Injection, U.S.P. (Ambot Solutions) 
and filter sterilized by suction filtration through a 0.20 micron plain 
membrane Nalge filter unit just prior t o injection. The non-drug-
treated (control) group was injected with 1.0 mg Nembutal intraperi-
toneally 30 minutes prior to radiation treatment. 
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Both control and experimen t al groups r eceived 60ro radiation. to 
the head only, using a 28 cm x 28 cm field blocked off with lead (0 . 20 
cm thick) to produce a 4 cm x 20 cm field and a source- to-skin distance 
(550) of 65 cm. The mice wer 1 radiated a t a rate of approximately 
295 rads/min with a Zoneguard Picke r V-9 60Co model with a f factor 
(roentgens/rads) of 0.957 , displacement factor of 0.985, chamber cor-
rection factor of 1.026. and a s tem correction fac tor of 1.0009 (when 
calibrated at 8 em x 8 em) . 
The experimental mice were divided into groups of ten each and were 
irradiated with 100 rad increments for each successive group f rom 3000-
3700 r ads . The control mice we.e also divided into groups of ten each 
and were irradiated with 100 rad increments for each successive group 
but ranging from 1200-1800 rads . 
Following radiation the mice were observed for deaths for a period 
of two weeks. Those deaths occurring from day 0-2 following radiation 
treatment were rela t ed to to ."icity and these animals were not used in 
the study. The per cent dead was plott~d against radia tion dose and 
the method of Litchfi~ld and Wilcoxon (13) was applied to det ermine the 
LOSO/8-10. 
Mice used for examinat ion of histological r adiation effects on 
salivary glands were divided into two groups. One group received 
500 mg/kg WR-2721 and radiat ion while the other group received only 
radiation. The mice were irradiated in the same manner as previously 
described for the oral radiation death study. 
Mice were sacrificed with an overdose of ether at different time 
intervals following radiation: 1 day, 1 week, 2 weeks, 3 weeks, 1 month, 
2 months, 3 months, 4 months, 5 months, and 6 months. Salivary glands 
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were excised and placed immediately in Bouin's fixative. After being 
in the Bouin' 5 fixative for 4 hours, the glands ",'ere transferred into 
70 per cent ethyl alcohol for an indefinite period of time in excess of 
15 minutes. Dehydration was c~r" ·. ted with three changes of 95 per 
cent ethyl alcohol for 15 minutes each followed by three changes in 100 
per cent ethyl alcohol for 15 minutes each. 
The tissue blocks were then cleared in two changes of chloroform 
for 15 minutes each. After clearing, the glands were infiltra ted with 
two changes of Paraplas t paraffin (melting point of 56-570 C) for 15 
minutes each in a Preiser Thelco Hodel II 17 heating oven (5 70 C) . This 
was followed by infiltra tion in another change of paraffin f or 15 
minutes in a Labline Vacuum Oven (16-24 inches water vacuum). 
The hardened blocks of tissue were sectioned both longitudinally 
and transversely into 5 micron sections with an AO Spencer "820" rotary 
microtome. The sect i ons were allowed to fa ll into a water floatat ion 
bath maintained at 44-450 C. Tce sections were then put onto albuminized 
(Hayer's Albumin Fixative) gl ass slides . These gl a ss slides were then 
rlaced into a heating oven a t 570 C and al lowed to stay until the paraf-
fin melted. 
The slides were then placed into three changes of xylene for 2 
minutes each and then the t issue sections were rehydrated with absolute 
e thyl alcohol , 95 pe r cent ethyl alcohol, and finally water. Rehy-
dration steps consisted of three changes of each of the above solutions 
for 2 minutes each. 
After rehydration, different sections from the same tissue block 
were stained using three different stains: (1) hematoxylin and eosin, 
(2) Hasson-trichrome, using aniline blue as the counterstain, and 
(3) mucicarmine, using freshly made ~ucicarmine ? repared by the 
modified Mayer's method (8); the r.egular Mayer ' s method was then 
used (14). 
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Aft e t" s a i ning was c , .. L ed t glas s cover sl ips we re applied with 
lar l eco SJ'nthet .!.c Resin MOllntj ue i'!cciium. The sect:ioned s alivary gland 
preperations \ver.e then examined with ligh t microscopy. 
Dogs weri! . .! t:;o;;od t o study the effects o f radiation on salivary 
functi ' <kin, ,,~,~ oral mucosa with and without WR-2721. Both female 
and male .,,:~grel dogs were used. They were mai:.tained on ad libitum 
feeding in ,29 cm long x 9' em wide x 74 em high aluminum-barred pens. 
The "'/~rage weight of the do gs us ed was ap proximately 18 kilograms . 
Eight do gs were divided into four groups of t wo dogs each. One dog 
from each group received radiation and llR-2721 while the other dog re-
ce ived only radiation. Both non-drug-treated (control) and drug-
treated (experimental) dogs were anesthesized with 26 mg/kg veterinary 
grade Nembutal (60 mg/ml) injected intravenously (20 gauge, 1 1/ 2" 
bevel needles) prior ~o radiation. The experimental dogs were injected 
intravenously with 70 mg/kg WR-272l 30 minutes prior to radiation . The 
drug was dissolved just before use and filter sterilized as described 
above . 
Both control and experimental dogs received radiation, to the left 
side o f the head only, us ing a 16.5 em x 20 Cl" tield blocked with lead 
(0.6 cm thick) to a field of 8.25 em x 10 em, thereby excluding rae i-
ation to the right side of the dog . During the r adiatiop treatment the 
dog was placed in a supine position with the bott0m of the lower jaw 
facing the x-ray radiation tube. The dogs were irradiated with a SSD 
of 50 em at a rate of approximately 122 rads/min using a 20 milliamp, 
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280 kilovolt powe r Picker X-Ray (Orthovol t age ) machine with a f factor 
of 0.948, half-va lue laye r of 1.32 rom copper , and an effective ene r gy of 
88 . 5 ki l o-elec tron volts. Li thium fluoride chips were placed inside 
the cheeks of both the rigr . ,I d left sides of the dogs and the doses 
of radiation were verified with a Victoreen 2800 Thermoluminescent 
Dosimeter Reader . Each of the fo ur g roup s of dogs r eceived a sin gle 
dose of radiation. The doses ranged f rom 1000 t o 2500 rads at 500 rad 
increments. 
Post-il"t il.!l a t ion salivary g1£.. :':' secr etions were measur~ci a t weekly 
intervals for one month fOLlowing radiation. Measure~ent s were t aken 
for both the right (non-irradia t ed) and left (irradiated) sides o f both 
the cor-tral and exp e riment al groups . 
The measuremen ts were t aken with the dogs in s upine positions under 
Nembuta l anesthesia. The mouths of the do gs were fi rst dried with 
gauzes, then pre- weighed Curity gauzes were placed in the buccal 
pouches of both the right 3nd left s ides . Ga uzes were also placed sub-
lingually . The mouth was tied loosely with a gauze . Pros t igmin 1:2000 
(0.5 mg/ml) wa s injected intravenously a t a. dose of 1.0 mg per do g . The 
gauzes were removed 15 minut es later and r eweighed . The difference in 
the gauze weight before and af t e r salivary collection was used to repre-
sent salivary flow from the right and left buccal pouches. Sublingual 
gauzes were discarded. Th ese collec t ed f l ows were pl ot t ed as a function 
of the time following radiation. Photographs we r e ~aken with a 
Ni kkorma t FTn camera, using Kodak Ektachro me-X ASA 64 color slide f ilm, 
to reco rd t he acute reactions of the hair, skin , and oral mucosa. 
RESULTS 
The LD50 /8-10 for t he control group of mice was calculated t o be 
1600 r ads (Figure 5) . wtereas the LD5U/B- 10 f~ r the experimental group 
of mice wa s found to be 3354 r ads (Figure 6). The dose modifying 
fac t or (D~rr) is 2. 1. calcula t ed as the ratio o f the LD50 experimental 
to the LD50 contro l gr oup . 
T3e toxic effec t of combined Nembutal and WR-272l was gr eat in the 
mice . It was found tha t the amount of Nembutal required for anes thes ia 
in the experimental group was one-half t he amount required to anesthesize 
t he cont ro l group. 
The radiation dose of 2000 rads r esulted in early dea th of all 
control mice and histological comparison at this radia t i on dose could 
not he made. Comparison of saliva r y gl ands i rradia ted with 1000 rad~ 
i n the contro l and experimenta : mice s hows s imilar histological changes 
in the serous gl ands (Table Ill). Mi ld degenerat ion appears as ear l y as 
day one, progressing to early r egenera t ion of t he serous portion be-
ginn ing at week two . Full regenera t ion of the serous portion appears 
t c no t be completed a t six months fol l owing trea t ment . Patchy a reas of 
normal serous cells and o the r areas of severe disor ganization are seen 
in both gr oups . 
The muco us glands in the control group show mild radiation damage 
after one month and full recovery appears a t s i x months. In the e xperi-
mental group. 1000 rads fails to produce any apparent damage to the 
mucous ce lls t hrough the s i x month period. 
25 
26 
Figure 5. Oral radiation death without radioprotection showing the 
LD50 /8-l0. 
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Figure 6. Oral radiation death with radioprotection showing the 
LDSO/8-l0. 
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TABLE III 
RADlATION HISTOLOGY OF SEROUS GLANDS AFTER RECEIVING 1000 RADS 
---------------1----------------------- --------- ----------- -------------
I 
I 
WITHOUT WR-2721 i :lr. ~ Remarkable 
WITH WR-2721 I Not Remarkab l e 
---------------t------------------------------------- -------------------
I 
I ONE WEEK 
WITHOUT WR-27211 Some Degenerative Changes; Some Lack of Organization 
WITH WR- l 721 I Some Degenerative Changes; Some Nuclear Hyperchromatism 
---------------t--------------------------------------------------------I TWO \.'EEKS 
WITHOUT WR- 27211 Cellular Hyperplas ia; Some Degenerative Changes; 
I Hyperchromatic Nuclei 
WITH WR-2721 : Cellular Hyperplas ia 
---------------+--------------------------------------------------------
: THREE WEEKS 
WITHOUT WR-2721: Not Remarkable 
WITH WR-2721 I Some Degenerative Changes 
---------------+--------------------------------------------------------
: ONE HONTH 
WITHOUT WR-2721: Not Remarkable 
WITH WR-272l : Not Remarkable 
. . _------------+--------------------------------------------------------
: TWO HONTHS 
WITHOUT WR-272l1 Cellular Hyperplasia; Degenerative Changes; Nuclear 
I Hyperchromatism 
\'~TH WR-2721 : Cellular Hyperplasia; Nuclea r Hyperchromatism 
---------------+--------------------------------------------------------I THREE HONTHS, EIGHT DAYS 
WITHOUT WR-272l: Hydropic Degeneration; HYDerchromatic Nuclei 
IJITH WR-272l : Cellular Degeneration ; Hyp erchromatic Nuclei 
---------------t--------------------------------------------------------
I 
I 
WITHOUT IJR-27211 
IHTH WR-2721 : 
I 
I 
FOUR HONTHS, ELEVEN DAYS 
Hydropic Degenera tion; Hyperchromatic Nuclei 
Cellular Degeneration; Celblar Hyperplasia; 
Hyperchromatism 
Nuclear 
---------------~--------------------------------------------------------
: FIVE HONTHS 
WITHOUT WR-272l1 Hydropic Degeneration; Large, H"perchromatic Nuclei 
WITH WR-2721 : Some Hydropic Degeneration 
---------------~--------------------------------------------------------I SIX HONTHS 
WITHOUT \'~-2721: Cellular Hyperplasia; Nuclear Hyperchroma tism 
WITH WR-272l I Cellular Hyperplasia; Nuclear Hyperchromatism 
---------------~--------------------------------------------------------
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Preliminary baseline salivary flows were incons i Stent in all dogs. 
The POst-radia tion saliva measu r ements of both Control and eXperimental 
dogs do not s how any consistent flow patterns (Figures 7 through 10). 
The r e is a general trend ho.eve r of lesser saliva ry seC r e tion from the 
l e ft Side of both Control and experimental dogs. 
There was a loss of pigment in the left bUccal Pouches of both 
Control and experimental dogs with the maxj~um loss ocCurring at O~e 
month fOllowing radiation. There Was almos t to tal loss of Pigment in 
the Control dog (Figure 11) followed by full restoration of pigment 
Within two months folloWing radiation (Figure 12). Loss of Pigment in 
the experimental dog was very Slight one month fOlloWing radiation 
(Figure 13) . This was also fallowed by full restoration of Pigment 
Within two mon t hs fOlloWing radiation (Figure 14). 
The oral cavity strUCtures at no time shOwed radia tion damage 
fOlloWing 1000 rads. Ve ry minimal hair l oss occurred at this low dOse 
t n the Control animal, whereas there was no hair loss in the expe rimen tal dog. 
MOderat e hair l oss occurred a t 1500 rads in the Control dog a t two 
months, Whereas there was no los s of hair in the dog receiVing the drug. 
There Was no hair loss in t he experimen t al dog two •• onths folloWing 
treatmen t with 2000 rads (Figure 15), Whereas the control member of the 
pair had total hair loss at th ~ t time (Figure 16). 
MOist desquamation of the skin occurred a t the 2500 rad level in the 
Control animal. Figure 17 Shows the Control dog two weeks fOllOWing 
2500 rads. Figure 18 shows the same dog with mOist desqUamation one 
month fOlloWing 2500 rads . Figure 19 shows the experimental dog two 
weeks fOlloWing 2500 rads . Figure 20 shows the same dog with only 
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Figur~ 7. Salivary secretion measurements by weight following 1000 rads 
of x-ray (orthovoltage) radiation. 
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Figure 8 . Salivary secretion measurements by weight following 1500 rads 
of x-ray (orthovoltage) radiation. 
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Figure 9. Salivary secretion measurements by weight following 2000 rads 
of x-ray (orthovoltage) radiation. 
Legend 
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Figure 10. Salivary secretion measurements by weight following 2500 rads 
of x-ray (orthovoltage) radiation. 
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Figure 11. Left buccal pouch showing example of pigment loss in control 
dogs one month following x-ray (orthovoltage) radiation. 
Figure 12 . Left buccal pO'Jch showing example of restora tion of pigment 
in control dogs two months following x-ray (orthovoltage ) 
radiation . 
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Figure 13. Left buccal pouch showing example of little pigment loss in 
the experimental dogs one month following x-ray (ortho-
voltage) r adiation. 
Figure 14. Left buccal pouch showing example of restoration of pigment 
in the experimental dogs two months following x-ray (ortho-
voltage) radiation. 
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Figure 15. Experimental dog two months following 2000 r ads of x- ray 
(orthovoltage ) r adiation showing no hair loss. 
Figure 16. Control dog two months following 2000 rads of x-ray (ortho-
voltage) radiation showing total hair loss of the left 
(irrad i ated ) s ide . 
.--
·a 
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Figure 17. Control dog two weeks following 2500 r ads of x-ray (or tho-
voltage) radiation. 
Figure 18. Control dog one month following 2500 rads of x-ray (ortho-
voltage) r adiation showing moist desquama tion of the skin. 
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Figure 19. Experimental dog two weeks following 2500 rads of x-ray 
(orthovoltage) radiation. 
Figure 20. Experimental dog one month following 2500 rads of x-ray 
(orthovoltage) showing moderate hair loss on the left 
(irradiated) side . 
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moderate hair loss one month following 2500 rads. 
The ora l mucosal reac tions were consistently greater in the control 
animals . The maximum acute r r.actions occurred at two weeks following 
radial. n. Animals r eceiving Iffi-2721 had faster healing of the effects 
of radiation . 
Fjgu~es 21 through 24 show the oral mucosal reactions of the 
control dog following treatment with 1500 rads. The experimental dog 
showed only a very slight reaction, similar to that seen in Figure 23, 
which appeared at two weeks following radiation and was gone by three 
weeks. The reaction in the control dog was s till present at three 
w~eks, but it was gone by four weeks following radiation. 
The oral macosa of the experimental dog receiving 2000 rads showed 
a larger reac tion, than the do g receiving 1500 rad s alone, at two weeks 
following radiation (Figure 25). All the oral mucosal radiation re-
action in the experimental dog receiving 2000 rads was gone by one 
month following radiation (Figure 26). The control dog showed a much 
larger radiation reaction, covering the entire area of the oral mucosa 
irradiated, two weeks following radiation (Figure 27). A slight re-
action was s till present at one month followin g radiation (Figure 28). 
Following 2500 r ads the cont ro l and experimen tal dogs showed simi-
lar reactions of the oral mucosa with the reac tion covering the total 
area irradiated. But the react ion oc~urred a t one week in the control 
dog and did not occur until two weeks in the experimental dog. 
Figure 29 shows t he reaction in the control dog one week following radi-
ation. Figure 30 shows the rea c tions st11l present at four weeks 
following radiation . Figure 31 shows the reaction in the experimental 
dog at two weeks following radiation. Figure 32 shows the reactions 
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gone by three weeks following r adiation. A s imilar oral mucosul re-
action e ff ec t occurr ed at 2500 r ads in the drug-trea ted animal and at 
1500 r ads in the non-drug-treat ed cnimal . The r a tio of these two radi-
ation doser , {ves a DMF of 1.67. 
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Figure 21. Oral mucosa "of the tongue in the control dog one week 
following 1500 r ads of x-ray (orthovoltage) radiation . 
Figure 22. Oral mucosa of the tongue in the control dog two weeks 
following 1500 rads of x-ray (orthovo1tage) radiation. 
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Figure 23. Oral mucosa of the tongue in the control dog three weeks 
following 1500 rads of x-ray (orthovoltage) radia tion show-
ing only a small area of rad ia tion reaction. 
Figure 24. Oral mucosa of the tongue in the control dog one month 
following 1500 rads of x-ray (orthovoltage) radiation. 
~lucosa is free of any radiation reaction. 
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Figure 25. Oral mucosa of the tongue in the experimental dog two weeks 
following 2000 rads of x-ray (orthovoltage) radiation. 
Figure 26. Oral mucosa of the tongue in the experimental dog one month 
foll~winF 2000 rads of x-ray (orthovoltage) radiation. 
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Figure 27. Oral mucosa of the tongue in the control dog two weeks 
fol l owing 2000 rads of x-ray (orthovoltage) radiation . 
Figure 28. Oral mucosa of the tongue in the control dog one month 
following 2000 rads of x-ray (orthovoltage) radiation. 
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Figure 29 . Oral mucosa of the tongue of the control dog one week 
following 2500 rads of x-ray (orthovoltage) radiation. 
Figure 30. Oral mucosa of the tongue of the control dog four weeks 
fol lowing 2500 rads of x-ray (orthovoltage) r adiation. 
" ;,-':/ 
. 'v ~ / " .... 
" ".J 
.' ' 
1 , 
\. , 
' - ').. 
, #j" " ~, 
'.~' . 
.... 
<', , 
\ 
.. 
" 
\ 
46 
Figure 31. Oral mucosa of the tongue of the experimental dog two weeks 
following 2500 rads of x-ray (orthovoltage) radiation. 
Figure 32. Oral mucosa of the tongue of the experimental dog three 
weeks following 2500 rads of x-ray (orthovoltage) radiation. 

DISCUSSION 
Even though the reason for the oral radiation death syndroit.'. 1s not 
known, a DMF of 2 .1 could be of great significance . This syndrome, 
which has been described only in mice (9), has been modified to a 
larger degree by 1,JR-2721 than any protective compound previously 
studied. This death point (ora l radiation death) may have little sig-
nificance in large animals, but it prevented the study of the effects of 
large doses of radiation on the histology of mouse salivary glands, as 
originally planned . The desire to use mice for the study of the effects 
of radiat ion on salivary gland histology stems from the fact that use 
of these s mall inbred animals would allow comparison studies of large 
numbers of genetically identical animals . Histological evaluation of 
salivary glands in this study is th erefore limited to low radiation 
dose i n mice for acute and later changes. Higher doses can be evalu-
ated in mongrel dogs . 
The salivary gland may be an organ for e xcretion or metabolism of 
WR-2721 which could explain the lack of protection observed in the 
salivary s e rous glands . It is apparent that the mucous glands are rela-
tively radioresistant because only mild radiation damage, follo~ed by 
full regeneration, was observed in the control mice . This is also ob-
served clinically in patients receiving radiation to the salivary 
glands . There is a quick reduction in the serous secretions, leaving 
the patient with thick mucous secretions (26). 
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Physiological changes in bo th the cont~ol and exper imental dog 
salivary glands were small er than expec t ed . The radia tion doses given 
far exceeded the equivalent doses used in human radiation therapy . 
SalivarY l~cretlon from the irradiated glands in both experiment a l and 
control animals however continued, al though at decreased l eve l s. 
Pos s i ble problems with this s tudy might include: 
1. There is unusual radioresistance of dog sal ivary tissue 
as compa red t o human salivary tis sue. 
2 . The method of saliva collection was inadequate. 
3 . Less than the intended dose of r adia tion was delivered . 
4. Diurnal variation masked the resul t s. 
5. The high concentra tion of 355 WR-27 2l seen in the auto-
radiographs of the salivary gland s represents excretion 
of this drug, similar to excret i on obse rved in the kidney (25). 
It i s mos t likely tha t the salivary gland is another or gan of ex-
c r e tion fo r WR- 272l. If this is true, then possibl y no pro tection 
would be expected. The kidney a l so shows high concentrations of 
355 WR-272l, but i t is not protected by the drug. The kidney merely 
exc r etes the drug. 
It is fe lt that th e method of saliva measurements was adequa t e . 
The mouth was dried with gauz e before insertion of pre-weigheJ gauzes . 
Gauzes we re also placed su~lingually t o prevent the saliva secreted 
the re from draining onto the pre-weighed gauzes in the buccal po uches . 
Since the gauzes used in the pouches did not become supersaturated and 
the mouth was qui te dry after they were removed, it seems the full 
amount o f saliva secreted was obtained. 
Both lithium fluoride dosimetry and the r adiation changes observed 
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in the skin and oral cavity indicate the actual doses delivered wer.e 
the planned radia tion doses. 
Preliminary sa liva r y secr e tions wer~ ,;ollected 1 0th in early 
mornin g and I' late evening , with the dogs on ad libitum feeding, and 
twelve hours witho ut food . No pattern CQulJ b~ found af t er these 
manipulations. Thi- mongrel dogs of course cO'j Id :Jt be compa·red 
with each other in t he sam(' mann~r as inb red mice were compa:Y:'eci . 
Protec t ion of the skin and oral mucosa \las readily apparent at two 
to four weeks in do gs r eceiving doses higher than 1000 r ads . The end 
point for comparison between the contro l and the experimental animals 
that was chosen was that effect which would be clinical ly acceptable. 
Al t hough there was pr otection against moist desquamation a t the 2500 rad 
level , this condition is rarely observed in clinical radiothe rapy unless 
bolus material for e lectron build-up is placed directly on the skin . 
The total-hair- loss end point resulted in a DMF of 1. 67. Higher 
DMF ' s of 2 . 0 and 2 . 4 have been reported for skin pr ot ect i on (17, 30), 
the r efore problems wi th thi s study mjght include: 
1. The period o f thirty w.inut es between i ntravenous injection 
of the drug and radiation was too long. This time period 
was chosen t o a llow greater concentration of the drug in 
the salivary gl ands. Autoradiogr aphic stud ies of 
35 . 5 ~~-272l shows tha t the skin clearing of the drug's 
r ap i d (25), therefo r e , higher DHF ' s for skin and oral 
mucosal protection might have been obtained if the radi-
a tion had been delivered 5-10 minutes f ollowing the drug 
injection. 
2 . Large field sizes in large animals have not been studied 
previously fo r skin protection. It is possible that the 
protective effec t might be grea t er when smal l e r areas are 
irradiated. 
3 . The orthovol t age mach '.... used in this s tudy wou l d be 
expected t o produce a n igher r eaction at t he skin s ur face 
than megavoltage machines. 
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It seems that WR- 272l has a definite protec t ive ac tion against 
ionizing radiation in o r al cavity s tructures . Th e protection is g r eater 
at lower reaction grades than at the high-dose end point of moist de-
s quamation . It i s mos t probab l e tha t the protective effect could be 
greater if the time between the drug injec t ion and radiation were l ess . 
One o f the most cotmnon compla ints of patien t s receiving head and 
neck radiation is a dry mouth due to the radia tion damage t o the 
salivary g l a nd s . Although this dru g in this s tudy was not shown t o pro-
vide protection of the salivar y serous glands , i t does gi ve promise of 
being useful c l i nically . The patient could possibly be protected f r om 
the acut e radiation reactions of the skin and ora l muc~sa using WR-2 721 . 
The toxicity noticed in the mice rece iving ~embuta l and WR- 272l was 
not apparent in the clogs . This probably is re l a t ed to the s i ze of the 
animal and the amount of WR- 272 l given. This would not be a problem 
with humans, as the patien t is ra re l y anesthes ized prior to radiotherapy. 
Addit iona l investigations of the radiop r o t ec tive effect of WR-272l 
a r e indicate d on the basis of findings r epor t ed in t his study. Some 
possible sugges tions for new studies might include: 
1 . The pro t ective effec t may be related to the field size 
of radiation . Studies with diffprent field s ize s could 
theref ore prove to be valuable . 
2. The protective effect may be different wh~n differ ent 
radiotherapy machines are used. An experi ment using 
kilovoltage and megavoltage energies .o1ou ld the r efore 
show differer ...... $ in protection . 
3. The protec t ive effect may be rela ted to the time be-
t ween the drug adminis tration a nd radiatio~ . Studies 
which var y t he times could show different D~W ' s at 
specific end points. 
4. Diffe r ent routes of adminis tra tion of the drug could 
poss ibly show different protect ion against t he same r adi-
o ion reaction . Comparison between oral, in Lr aper itoneal , 
topical, and intravenous administ rations s hould be made. 
5 . Finally. since this study s ugges t s that the salivary gland 
may be another organ of exc r e tion of WR-2721, further 
radiolabe lled WR-2721 studies should be made t o help trace 
the path of the drug administer ed sys t emically. 
51 
As the informat ion about WR-2721 increase .. it ougges t s tha t it woul d 
be of value in clinical rc 'l.a tion therapy fo r the protection of normal 
tissues from t he damaging e ffects of radiation. 
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